Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
出版年份 2020 全文链接
标题
Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-08-13
DOI
10.1111/jcmm.15730
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians
- (2020) Consuelo Borrás et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts
- (2020) Jessica Petiti et al. Journal of Clinical Medicine
- Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways
- (2019) Jessica Petiti et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells
- (2019) Valentina Rosso et al. Journal of Clinical Medicine
- Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
- (2018) Denis Tvorogov et al. Science Advances
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Leukemic Transformation in Myeloproliferative Neoplasms
- (2017) Meera Yogarajah et al. MAYO CLINIC PROCEEDINGS
- Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
- (2016) T Balligand et al. LEUKEMIA
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
- (2015) S Cerquozzi et al. Blood Cancer Journal
- The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
- (2015) Lucia Mazzacurati et al. Oncotarget
- ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway
- (2014) Marco Lo Iacono et al. INTERNATIONAL JOURNAL OF CANCER
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
- (2012) Raquel Tognon et al. Journal of Hematology & Oncology
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Down-regulation of the JAK2/PI3K-mediated signaling activation is involved in Taiwan cobra cardiotoxin III-induced apoptosis of human breast MDA-MB-231 cancer cells
- (2010) Kuei-Li Lin et al. TOXICON
- Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells
- (2008) A. Zeuner et al. BLOOD
- ABT-737, proving to be a great tool even before it is proven in the clinic
- (2008) D L Vaux CELL DEATH AND DIFFERENTIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now